Servier completes the acquisition of Day One Biopharmaceuticals
Acquisition expands Servier's position in oncology with tovorafenib marketed as OJEMDATM in the U.S. in pediatric low-grade glioma. Transaction also includes a strong oncology pipeline of clinical stage assets in rare cancers with high unmet needs. Transaction represents total equity value of approximately $2.5 billion. SURESNES, France, April 23, 2026 /PRNewswire/ --...
Published Clinical Study Illustrates Benefits of Promentum® Recover as Low-Dose Solution for Post Exercise Recovery
MOMENCE, Ill., April 23, 2026 /PRNewswire/ -- A recently published human clinical study demonstrates that Promentum® Recover, a patent-pending formula from FutureCeuticals anchored by calcium fructoborate in combination with low doses of turmeric and pomegranate extracts, delivers statistically significant post‑exercise recovery benefits. Promentum® Recover was shown to deliver a unique suite...
Fosun Health Strengthens Regional Presence at GlobalHealth Asia-Pacific Forum 2026, Showcasing “China Solution” and Winning Three Major Awards
JAKARTA, Indonesia, April 23, 2026 /PRNewswire/ -- Fosun Health made a prominent debut at the GlobalHealth Asia-Pacific Healthcare Insights & Leadership Forum 2026, held alongside the GlobalHealth Asia-Pacific Awards 2026 at the Grand Hyatt Jakarta, joining a distinguished community of healthcare leaders, innovators, and decision-makers from across the Asia-Pacific region. During the Forum, Mr. Hu Hang, Chairman and CEO...
Mabwell Initiates Phase III Clinical Study of its Nectin-4-Targeting ADC 9MW2821 for the Treatment of Triple-Negative Breast Cancer
SHANGHAI, April 23, 2026 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announces the initiation of a Phase III clinical study of its proprietary Nectin-4-targeting ADC (R&D code: 9MW2821) for the treatment of triple-negative breast cancer (TNBC). 9MW2821 is the world's first Nectin-4 ADC to enter Phase III clinical study for TNBC. This...
2026 ASCO | Mabwell to Present Latest Clinical Data on 9MW2821 Combined with Toripalimab for Urothelial Carcinoma in Oral and Poster Presentations
SHANGHAI, April 23, 2026 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that two latest clinical study results of its Nectin-4-targeting ADC 9MW2821 in combination with toripalimab for urothelial carcinoma will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, USA from May 29 to June...
MINJUVI® (tafasitamab) for Relapsed or Refractory Follicular Lymphoma Approved in Australia
Minjuvi® (tafasitamab), in combination with rituximab and lenalidomide, is the first and only chemotherapy-free CD19 and CD20 dual-targeted immunotherapy combination regimen to be approved in Australia for adults with relapsed or refractory follicular lymphoma (R/R FL) (Grade 1-3a).1,2 Despite the availability of existing treatments, R/R FL remains incurable, is characterised by...
WuXi Biologics Receives South Korea MFDS GMP Certification to Enable Commercial Manufacturing of Bispecific Antibody Therapeutics
WUXI, China, April 23, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced that three of its manufacturing facilities in Wuxi – Drug Substance Facility 5 (MFG5), Drug Product Facility 2 (DP2), and Drug Product Packaging Center (DPPC) – have received GMP certification from South Korea Ministry of Food and Drug Safety...
AACR 2026 | Abbisko Therapeutics Showcases Six Research Advances Highlighting pan-KRAS, 4th Generation EGFR, and Synthetic Lethality Approaches
SAN DIEGO, April 23, 2026 /PRNewswire/ -- Abbisko Therapeutics (HKEX: 02256) announced that the company presented six latest preclinical and translational research findings in poster sessions at the American Association for Cancer Research (AACR) Annual Meeting, held from April 17 to 22, 2026, in San Diego, USA. The presentations span multiple key...
2026 ASCO Preview | Alphamab Oncology to Present Clinical Data of TROP2/HER3 Bispecific ADC JSKN016 for HER2-Negative Breast Cancer
SUZHOU, China, April 23, 2026 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) today announced that the results from a Phase I clinical study (JSKN016-101, NCT06592417) of its first-in-class TROP2/HER3 bispecific antibody-drug conjugate (ADC) JSKN016, for the treatment of HER2-negative locally advanced or metastatic breast cancer (BC), will be presented as a poster at the 2026 American Society of Clinical...
BioEngine Launches UltraFeed CHO Supplement, Boosting Titers by Up to 48%
SHANGHAI, April 23, 2026 /PRNewswire/ -- Shanghai BioEngine Sci-tech Co., Ltd. announced the launch of UltraFeed, a next-generation fed-batch supplement designed to elevate CHO cell productivity in monoclonal antibody, bispecific, and recombinant protein manufacturing. Across diverse cell lines and molecule formats, UltraFeed delivers an average titer increase of 25%, with select programs achieving gains as high as 48% when...
